Cervical cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• TP53 2
• PD-1 19
• PD-L1 12
• PI3K 3
• AKT 1
• CTLA-4 7
• HER2 9
• CTNNB1 0
• mTOR 0
• STAT3 0
• VEGF 3
• EGFR 2
• MYC 0
• MAPK 0
• PTEN 2
• NRF2 1
• PIK3CA 3
• ERK 0
• PARP 0
• AMPK 0
• JAK 0
• TROP2 4
• YAP 0
• BRCA1 2
• GPX4 0
• HIF-1 0
• IL-6 0
• TNF 0
• FOXP3 0
• KRAS 0
• B7-H3 3
• BCL-2 0
• BRCA2 2
• HER3 1
• JNK 0
• MMP-9 0
• STING 0
• STK11 0
• AXL 0
• CD47 0
• COX-2 0
• EZH2 0
• FAK 1
• HDAC 0
• HMGB1 0
• PPAR 0
• PRAME 0
• ATM 0
• CD40 0
• CXCR4 0
• IDH 1
• LAG-3 0
• METTL3 0
• NF1 0
• NOTCH1 0
• PKM2 0
• PRMT5 0
• SHP2 0
• SIRT1 0
• ALK 0

24 of 2,705 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NINR · R01

  Community Health Centers Achieving Metrics and Primed for Success

  University of Pennsylvania· Philadelphia, United States· US$762,815 awarded in fiscal year 2026· until Jun 2031

• NIH NCI · R01

  Enhancing Cervical Cancer Screening through Integrated Care in Rural North Carolina

  Univ of North Carolina Chapel Hill· Chapel Hill, United States· US$607,403 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · U01

  Comparative Modeling to Inform Cervical Cancer Prevention Policies and Practice in the United States

  Tulane University of Louisiana· New Orleans, United States· US$1,084,939 awarded in fiscal year 2026· until Aug 2031

• NIH NIDCR · R56

  Screening for HPV-related oropharyngeal cancer

  Johns Hopkins University· Baltimore, United States· US$979,697 awarded in fiscal year 2026· until Sept 2028

• NIH NCCIH · R34

  Feasibility Study to Increase use of non-Pharmacological Therapies for Chronic Low Back Pain

  Rand Corporation· Santa Monica, United States· US$757,923 awarded in fiscal year 2026· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  Cervical Cancers Escaping HPV Screening: Decoding HPV-Independent Carcinogenesis through Multi-Omics Profiling (ESCAPE-HPV)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €1,493,450· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-RIA

  Offering combined HPV vaccination and HPV test-based cervical screening to vulnerable populations. A hybrid efficacy and implementation study. (HPV-FASTER-Implement)

  Institut National de la Sante Et de la Recherche Medicale· Paris, France· EU contribution €6,602,445· until Dec 2029· 8 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Understanding vaccination hesitancy and evaluating single dose and gender-neutral vaccination for improving uptake of HPV vaccines in West and East Africa. (IMPROVE-HPV)

  Institut Catala D'oncologia· Hospitalet de Llobregat, Spain· EU contribution €3,613,288· until May 2028· 4 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Engineering B cells to fight cancer (EngineerBcells)

  Tel Aviv University· Tel Aviv, Israel· EU contribution €1,996,250· until Sept 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Dual screening by Spectral Artificial Visual Examination (SAVE) for Female Genital Schistosomiasis (FGS) and cervical cancer. Digital, new, low-cost, and simple screening and training. (DUALSAVE-FGS)

  Oslo Universitetssykehus Hf· Oslo, Norway· EU contribution €7,984,441· until Aug 2027· 6 countries

10 of 326 running projects, newest first. Listed amounts together: US$202.2m + €23.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

  NCT05337735· M.D. Anderson Cancer Center· Updated 13 Oct 2026

  “PI Request”Registry text, quoted unchanged. Source

• Terminated

  MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer

  NCT03634267· M.D. Anderson Cancer Center· Updated 15 Sept 2026

  “PI Request”Registry text, quoted unchanged. Source

• Terminated

  A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer

  NCT04630353· AstraZeneca· Updated 14 Sept 2026

  “Sponsor decision.”Registry text, quoted unchanged. Source

• Suspended

  CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

  NCT07181720· Chongqing Precision Biotech Co., Ltd· Updated 11 Sept 2026

  “Sponsor stopped the study.”Registry text, quoted unchanged. Source

• Terminated

  Impact of Basic Needs Assessment and Support to Improve Colposcopy Show Rate

  NCT05458960· Washington University School of Medicine· Updated 31 Aug 2026

  “Staffing issues”Registry text, quoted unchanged. Source

• Withdrawn

  CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV

  NCT07090174· University of California, San Diego· Updated 19 Aug 2026

  “Study withdrawn prior to participant enrollment due to lack of study product.”Registry text, quoted unchanged. Source

• Suspended

  Paclitaxel Therapeutic Drug Monitoring in Cancer Patients

  NCT03987555· Wake Forest University Health Sciences· Updated 13 Aug 2026

  “Funding”Registry text, quoted unchanged. Source

• Terminated

  A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

  NCT05572684· NextCure, Inc.· Updated 13 Aug 2026

  “Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.”Registry text, quoted unchanged. Source

• Terminated

  First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

  NCT04974944· Sun Yat-Sen University Cancer Center· Updated 29 Jul 2026

  “No superior PFS in study group among the enrolled patients. Company R\&D strategy shifted; funding discontinued, study terminated.”Registry text, quoted unchanged. Source

• Terminated

  Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

  NCT06022757· Evopoint Biosciences Inc.· Updated 23 Jul 2026

  “Strategic decision by Sponsor.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

  NCT04491942· National Cancer Institute (NCI)· Source

• Phase 2 Pan-Tumor Trial of R-DXd for Advanced/Metastatic Solid Tumors

  NCT06660654· Daiichi Sankyo Inc.· Source

• SCREEN Yourself for Cancer

  NCT07927686· Milton S. Hershey Medical Center· Source

• Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

  NCT06079671· AstraZeneca· Source

• High-risk HPV Testing With Pap Smear Triage for Cervical Cancer Screening in Women Aged 50 and Older in Ethiopia

  NCT07929246· University Medical Center Groningen· Source

• A Cervical Cancer Prevention Program in Kenya

  NCT06411938· Indiana University· Source

• Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

  NCT07061977· National Cancer Institute (NCI)· Source

• Developing a Gynecologic Cancer Health Promotion Community Engagement Program

  NCT07910162· Abramson Cancer Center at Penn Medicine· Source

• A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

  NCT06459180· Merck Sharp & Dohme LLC· Source

• A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  NCT07216703· Merck Sharp & Dohme LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 28
• Organoids 10
• Mendelian Randomization Analysis 14
• CRISPR-Cas Systems 21
• Gene Expression Profiling 70
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 18
• Metabolomics 9
• Mass Spectrometry 4
• Flow Cytometry 25
• Immunohistochemistry 46
• Liquid Biopsy 8
• Circulating Tumor DNA 6
• Xenograft Model Antitumor Assays 66
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 92
• Machine Learning 65
• Deep Learning 50
• Cohort Studies 82
• Genome-Wide Association Study 15

• Integrated Microfluidic CRISPR-Based Diagnostic Device for Rapid Testing of HPVs.

  Biosensors (Basel), Oct 2026

• Development of a CRISPR/dCas9-based membrane-assisted colorimetric assay for detection of high-risk HPV16 and HPV18: a proof-of-concept study.

  Mol Biol Rep, Jul 2026

• CRISPR/Cas12a-based dual-modal signal platform using MIL-101(Fe) for colorimetric and electron spin resonance detection of HPV-16 nucleic acid.

  Biosens Bioelectron, Jun 2026

• CRISPR/Cas in gynecologic cancers: A review of experimental and therapeutic applications.

  Indian J Cancer, Jun 2026

• One-tube, protospacer adjacent motif-free and AI-enhanced CRISPR/Cas12a platform for ultra-sensitive detection of human papillomavirus 16 double-stranded DNA.

  Int J Biol Macromol, May 2026

• Machine learning-enabled smartphone CRISPR-Cas12a lateral flow platform for sensitive detection of circulating HPV DNA.

  Biosens Bioelectron, May 2026

• MXene-based CRISPR/Cas9 nanoplatform targeting FABP5 for ROS amplification and synergistic photothermal/photodynamic therapy of cervical cancer.

  J Nanobiotechnology, Apr 2026

• CRISPR-Cas system: recent advancements in prompt diagnosis of high-risk HPV genotypes in cervical cancer.

  Expert Rev Mol Diagn, Apr 2026

• What If Trojan Horse Nanoparticles Could Change the Game for HPV Gene-Targeted Therapies?

  J Med Virol, Apr 2026

• A tailored phosphorothioate coordinator enables CRISPR/Cas in-situ amplification.

  Nucleic Acids Res, Feb 2026

See which targets of this disease your abstract mentions, and go to the people working on them.